Lancet:非洲儿童白喉-百日咳-破伤风疫苗接种变化研究

2019-05-08 MedSci MedSci原创

尽管在非洲疫苗接种取得了重大进步,但在整个非洲大陆,DPT覆盖存在较大的国家和地区的不平等现象

常规儿童疫苗接种是最具成本效益、最成功的公共卫生干预措施之一。近日研究人员对非洲儿童白喉-百日咳-破伤风(DPT)疫苗接种率进行了考察。

研究人员对2000-2016年期间,49个非洲国家的881268名儿童数据进行了考察,采用贝叶斯地理统计模型,根据2017年全球疾病、伤害和风险因素研究的结果进行校准,得出2000-2016年期间52个非洲国家12至23个月儿童白喉-百日咳-破伤风(DPT)疫苗接种率。

2000-2016年,非洲二级行政单位的三剂量(DPT 3)估计覆盖率增加了72.3%,但在非洲国家之间和国家内部,DPT覆盖面仍然存在巨大的地域不平等。2016年,在52个国家中,仅有29个国家的第二个行政地区的DPT3覆盖率差异超过25%,52个国家中只有2个国家(摩洛哥和卢旺达)实现了全球疫苗行动计划目标(覆盖率达到80%以上)。在萨赫勒地区、索马里、埃塞俄比亚东部和安哥拉发现了大面积低的DPT3覆盖率(≤50%),在萨赫勒、索马里、埃塞俄比亚东部、几内亚和安哥拉的首剂量(DPT1)的覆盖率(≤50%)和接种完成率(≥30%儿童未完成3剂接种)较低。

尽管在非洲疫苗接种取得了重大进步,但在整个非洲大陆,DPT覆盖存在较大的国家和地区的不平等现象。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830065, encodeId=6b66183006517, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 31 18:17:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257870, encodeId=7c5f125e870a1, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361726, encodeId=b03a1361e2632, content=<a href='/topic/show?id=31d9e346426' target=_blank style='color:#2F92EE;'>#破伤风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73464, encryptionId=31d9e346426, topicName=破伤风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391726, encodeId=8d9c1391e26de, content=<a href='/topic/show?id=f5a8e1878f0' target=_blank style='color:#2F92EE;'>#百日咳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71878, encryptionId=f5a8e1878f0, topicName=百日咳)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515761, encodeId=afe01515e61d2, content=<a href='/topic/show?id=1efde166406' target=_blank style='color:#2F92EE;'>#白喉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71664, encryptionId=1efde166406, topicName=白喉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eb510868243, createdName=ms8538335253054589, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
    2020-03-31 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830065, encodeId=6b66183006517, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 31 18:17:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257870, encodeId=7c5f125e870a1, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361726, encodeId=b03a1361e2632, content=<a href='/topic/show?id=31d9e346426' target=_blank style='color:#2F92EE;'>#破伤风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73464, encryptionId=31d9e346426, topicName=破伤风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391726, encodeId=8d9c1391e26de, content=<a href='/topic/show?id=f5a8e1878f0' target=_blank style='color:#2F92EE;'>#百日咳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71878, encryptionId=f5a8e1878f0, topicName=百日咳)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515761, encodeId=afe01515e61d2, content=<a href='/topic/show?id=1efde166406' target=_blank style='color:#2F92EE;'>#白喉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71664, encryptionId=1efde166406, topicName=白喉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eb510868243, createdName=ms8538335253054589, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1830065, encodeId=6b66183006517, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 31 18:17:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257870, encodeId=7c5f125e870a1, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361726, encodeId=b03a1361e2632, content=<a href='/topic/show?id=31d9e346426' target=_blank style='color:#2F92EE;'>#破伤风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73464, encryptionId=31d9e346426, topicName=破伤风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391726, encodeId=8d9c1391e26de, content=<a href='/topic/show?id=f5a8e1878f0' target=_blank style='color:#2F92EE;'>#百日咳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71878, encryptionId=f5a8e1878f0, topicName=百日咳)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515761, encodeId=afe01515e61d2, content=<a href='/topic/show?id=1efde166406' target=_blank style='color:#2F92EE;'>#白喉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71664, encryptionId=1efde166406, topicName=白喉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eb510868243, createdName=ms8538335253054589, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
    2019-05-10 wjywjy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1830065, encodeId=6b66183006517, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 31 18:17:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257870, encodeId=7c5f125e870a1, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361726, encodeId=b03a1361e2632, content=<a href='/topic/show?id=31d9e346426' target=_blank style='color:#2F92EE;'>#破伤风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73464, encryptionId=31d9e346426, topicName=破伤风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391726, encodeId=8d9c1391e26de, content=<a href='/topic/show?id=f5a8e1878f0' target=_blank style='color:#2F92EE;'>#百日咳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71878, encryptionId=f5a8e1878f0, topicName=百日咳)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515761, encodeId=afe01515e61d2, content=<a href='/topic/show?id=1efde166406' target=_blank style='color:#2F92EE;'>#白喉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71664, encryptionId=1efde166406, topicName=白喉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eb510868243, createdName=ms8538335253054589, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1830065, encodeId=6b66183006517, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 31 18:17:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257870, encodeId=7c5f125e870a1, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361726, encodeId=b03a1361e2632, content=<a href='/topic/show?id=31d9e346426' target=_blank style='color:#2F92EE;'>#破伤风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73464, encryptionId=31d9e346426, topicName=破伤风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391726, encodeId=8d9c1391e26de, content=<a href='/topic/show?id=f5a8e1878f0' target=_blank style='color:#2F92EE;'>#百日咳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71878, encryptionId=f5a8e1878f0, topicName=百日咳)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515761, encodeId=afe01515e61d2, content=<a href='/topic/show?id=1efde166406' target=_blank style='color:#2F92EE;'>#白喉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71664, encryptionId=1efde166406, topicName=白喉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eb510868243, createdName=ms8538335253054589, createdTime=Fri May 10 05:17:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]

相关资讯

全球领先种疟疾疫苗在非洲试点推广

据新华社电 世界卫生组织 4 月 23 日宣布,全球第一种也是迄今唯一一种被证实有预防效果的疟疾疫苗开始在非洲国家马拉维试点推广,随后还将在加纳和肯尼亚试点推广,为拯救成千上万儿童的生命带来了新希望。

疫苗会经常导致严重副作用?欧盟呼吁驳斥有关疫苗的虚假信息

最新调查显示,不少欧洲人对疫苗存有误解。欧盟委员会4月26日表示,应继续采取措施提高疫苗接种率、驳斥有关疫苗的虚假信息。

中国疫苗可预防传染病发病率降至历史很低水平

“今天,我依然理直气壮告诉大家,中国疫苗很好,是全球最好的疫苗之一,不能对中国的疫苗失去信心,不要对预防接种失去信心。” 4月23日,随着中国科学院院士、中国疾控中心主任高福一番慷慨激昂的宣讲,中国疾控中心儿童预防接种日的主题宣传活动进入高潮。

自然筛选人类?这群人疯了,举行麻疹病毒传播party!

今年,全球出现了麻疹疫情爆发,包括美国、德国、日本等在内的发达国家都没能幸免于外。菲律宾则有超过1万4000起确诊麻疹病例,其中238人死亡。

更有效疟疾疫苗将大规模测试 可在实验室中提供100%防护

一种能够对疟疾提供100%防护的疟疾疫苗将首次在一项大规模临床试验中进行测试,从而研究其在真实条件下的有效性。

香港诊所被曝给内地人打水货疫苗 给本地人用正品

据香港大公报报道,大公报记者上月目睹一名医生以“闪电手”撕包装,为客人接种水货HPV九价疫苗,短短一小时内已有十多名客人等待接种,诊所只收现金或由中介先行收费,一天生意额估计高达二十万元。诊所运作十分神秘,门口广告牌以医学美容中心遮掩,且只接待内地游客,只能通过中介预约接种疫苗。经记者追查发现,这名医生被揭露替客人打“水货针”后,曾急忙向某药业公司的董事汇报兼“备案”,「水货针」来源秘密,正一层层